Browse drugs

…ncrease (38%, p = 0.07).Conclusions In this multicenter cohort, nintedanib was associated with a significant reduction in ILD progression,…

…Pulmonary fibrosis is a progressive disease, often treated with nintedanib. However, its use is frequently associated with adverse effects…

…ype with functional decline. Antifibrotic therapy, particularly nintedanib, has significantly improved management by slowing forced vital …

…Background and Importance Nintedanib, a tyrosine kinase inhibitor with antifibrotic activity, is app…

…ered energy metabolism during fibrotic activation. Importantly, nintedanib pretreatment reduced both fibrotic gene expression (figure 2C) …

…33%. Longest use (days) was at 3192 for Nintedanib and 3127 for Pirfenidone. Since inception, RN/RPh-led monitoring has increased from 769 …

…eline and if experienced as a subsequent event after commencing nintedanib therapy.…

…(p=0.007), demonstrating enhanced receptor density (figure 1D). TGF-b1 dose-dependently induced BAG3 protein secretion in healthy fibr…

…Merkt W, et al. Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associa…

…in 4 (17.4%), 7 (28.0%) and 11 (40.7%) patients in the placebo, nerandomilast 9 mg and 18 mg BID groups, respectively. Rates of treatment dis…

…t treatment for pulmonary fibrosis is limited to nintedanib and pirfenidone, which slow but do not halt or reverse the progression of the d…

…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…